Még nem toboroz
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026-525763-40-00· 2. fázis· French Innovative Leukemia Organization (F.I.L.O.).· Forrás
Még nem toboroz
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· 4. fázis· University Hospital, Clermont-Ferrand· Forrás
Toboroz
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage:
a randomised, double-blind, placebo-controlled, phase 3 trial
PEACH 2
2024-515663-59-00· 3. fázis· Hospices Civils De Lyon· Forrás
Még nem toboroz
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· 3. fázis· Fondation A De Rothschild· Forrás
Még nem toboroz
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· 3. fázis· Centre Hospital Region Metz Thionville· Forrás
Toboroz
Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.
2026-526775-27-00· 2. fázis· Laboratoires Kol· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Még nem toboroz
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
NCT07624799· 2. fázis· French Innovative Leukemia Organisation· Forrás
Fut, nem toboroz
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· 3. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT06656598· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT06529718· 2. fázis· UNICANCER· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06180382· 4. fázis· Centre Hospitalier Universitaire de Saint Etienne· Forrás
Toboroz
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
NCT06572735· Hospices Civils de Lyon· Forrás
Contact: Ambroise Dr LAUBY, MD
Toboroz
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial
2024-514633-38-00· 3. fázis· Centre Hospitalier Universitaire Amiens Picardie· Forrás
Fut, nem toboroz
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
NCT05782127· 1/2. fázis· Groupe Francophone des Myelodysplasies· Forrás
Fut, nem toboroz
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· 1/2. fázis· Groupe Francophone des Myelodysplasies· Forrás
Toboroz
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· 2/3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Fut, nem toboroz
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Lezárult
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
NCT02967289· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
NCT02355379· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00005584· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás